Merck KGaA, Cancer Research U.K., Cardiff University, The Institute of Cancer Research deal

Merck's Merck Serono S.A. unit received rights to develop preclinical molecules against the Wnt pathway to treat cancer discovered under a completed four-year research collaboration between the unit, the institute, Cardiff and Cancer Research's Cancer Research Technology (CRT) commercial arm. CRT will receive an upfront license fee and is eligible for milestones, plus royalties. CRT will share revenue with the institute and Cardiff. ...